Article
Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.
Oncology research and treatment - 1 Jan 2020
Zhuo Ze-Guo, Zhu Yun-Ke, Deng Han-Yu, Li Gang, Luo Jun, Alai Gu-Ha, Lin Yi-Dan
Abstract excerpt
INTRODUCTION: Platinum is widely used in the treatment of esophageal cancer. In clinical practice, it is significant to distinguish patients who respond to platinum from those who do not. Excision repair cross-complementation group 1 (ERCC1) is thought to be the key in the resistance to platinum. However, whether it is related to the platinum-based chemotherapy response on real esophageal cancer patients is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
